Clinical Trial Update: A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093) [Phase 1]

View source ↗

Summary

This is a Phase 1 trial evaluating Niaspan (nicotinic acid) on endothelium-dependent and endothelium-independent vascular reactivity in individuals with dyslipi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• Niaspan (niacin (nicotinic acid))

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dyslipidemia | Phase 1 | Status: COMPLETED